Leyva-Grado Victor H, Palese Peter
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Antiviral Res. 2017 Jun;142:12-15. doi: 10.1016/j.antiviral.2017.03.002. Epub 2017 Mar 7.
Oseltamivir is an influenza neuraminidase inhibitor that along with supportive therapy has shown to help critically ill patients infected with H7N9 and H1N1pdm influenza virus strains to recover from disease. The standard of care recommends the administration of oseltamivir via oral route which represents difficulties in patients with gastrointestinal complications. Here we tested the use of aerosol administration of oseltamivir to treat mice infected with influenza A/H7N9 virus or influenza A/H1N1pdm virus and directly compared this approach to the standard of care, oral administration. Using nose only delivery of aerosolized oseltamivir we observed a significant increase in efficacy of the treatment compared to oral administration characterized by reduced body weight loss, increased survival rate and dose sparing. The preclinical data presented here supports the possibility of using this approach in clinical settings.
奥司他韦是一种流感神经氨酸酶抑制剂，与支持性疗法一起已被证明有助于感染H7N9和甲型H1N1流感病毒株的重症患者从疾病中康复。护理标准建议通过口服途径给予奥司他韦，这对有胃肠道并发症的患者来说存在困难。在此，我们测试了雾化吸入奥司他韦治疗感染甲型H7N9流感病毒或甲型H1N1流感病毒的小鼠，并将这种方法与护理标准（口服给药）进行了直接比较。通过仅经鼻递送雾化奥司他韦，我们观察到与口服给药相比，治疗效果显著提高，表现为体重减轻减少、存活率提高和剂量节省。此处呈现的临床前数据支持了在临床环境中使用这种方法的可能性。
